## **Brexafemme (ibrexfungerp) Prior Authorization Request Form Caterpillar Prescription Drug Benefit**

Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION	
LAST NAME:	FIRST NAME:
PHONE NUMBER:	DATE OF BIRTH:
STREET ADDRESS:	I
CITY:	STATE: ZIP CODE:
PATIENT INSURANCE ID NUMBER:	I

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

MALE FEMALE HEIGHT (IN/CM): \_\_\_\_\_ WEIGHT (LB/KG): \_\_\_\_\_ ALLERGIES: \_\_\_\_\_

#### PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): \_\_\_\_\_\_

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: \_\_\_\_\_

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
DURATION OF THERAPY (SPE	<b>RENEWAL</b> CIFIC DATES):	IF RENEWAL: DATE THERAPY INITIATED:			

Continued on next page



# Brexafemme (ibrexfungerp) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1 HAS THE DATIENT TRIED ANY OTHER	MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR		
	•	-		
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
Vulvovaginal candiadiasis(VVC)				
Recurrent vulvovaginal candidiasis(RVVC)				
Other diagnosis:ICD-	10			
3. REQUIRED CLINICAL INFORMATION	PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
PRIOR AUTHORIZATION.				
Clinical Information:				
	tient as part of a treatment regimen spe	scified within a sponsored clinical		
• • • •	tient as part of a treatment regimen spe	ecined within a sponsored ciffical		
trial? 🗆 Yes 🗆 No				
Has patient had at least one course of	topical antifungal therapy? <ul> <li>Yes</li> <li>No</li> </ul>	o Please submit dates.		
Has patient had at least 2 courses of o	ral fluconazole 150mg? 🗆 Yes 🗆 No Ple	ease submit dates.		
-	-			
Does patient have a contraindication t	o an azole antifungal? 🗆 Yes 🛛 No Plea	ase submit chart documentation.		
Renewal Requests:				
-	lowentoms and diagnosis of vulvousgin	al candidiacis (\/\/C\2      Vac        No		
is patient continuing to have signs and	symptoms and diagnosis of vulvovagin			
•	oses, symptoms, medications tried or fai	iled, and/or any other information the		
physician feels is important to this rev	iew?			
Please note: Not all drugs/diagnosis are	e covered on all plans. This request may	be denied unless all required		
information is received.				
ATTESTATION:   attest the information	provided is true and accurate to the bes	st of my knowledge. I understand that		
the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical				
information necessary to verify the accuracy of the information reported on this form.				
information necessary to verify the accuracy of the information reported on this form.				
	1	Data		
Prescriber Signature or Electronic I.D.	Verification:	Date:		
<b>CONFIDENTIALITY NOTICE:</b> The documents accompanying this transmission contain confidential health information that is legally privileged. If				
you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these desuments is strictly prohibited. If you have received this information in array places notify the conder immediately (via return EAX)				
of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.				
and arrange for the return of destruction of the				



## Brexafemme (ibrexfungerp) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_\_

MEMBER'S FIRST NAME: \_\_\_\_\_

### FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program Attn: CP - 4201

P.O. Box 64811 St. Paul, MN 55164-0811